Objectives To analyze the rate of remissions in RA pts treated with tocilizumab (TCZ) on self-assessment index.
Methods The study included 42 RA pts, predominantly female, 86% were RF-positive and, 84% - ACCP-positive, mean age 50,5±3,1 y, mean disease duration 5,6±4,74 y., high disease activity was established in 93% patients. Prior to TCZ all pts were receiving DMARDs, mostly methotrexate at average dose 15,0±2,7 mg/week; 14,3% pts - leflunomide 20 mg/day; 11,9% - sulfasalazine 2 g/day for at least 3 months without any improvement. TCZ 8 mg/kg was administered every 4 weeks during 24 weeks. Treatment outcomes were assessed by patients using RAPID-3, DAS28, CDAI, SDAI.
Results Before therapy average RAPID-3 was 15,6 [11,5;18,85]. After first infusion remission by RAPID-3 scale was achieved in 14% patients, at week 12 – in 20,3%, after 16 weeks - in 25%, by week 20 – in 30,5%, by week 24 - in 33,3% patients. After 6 month of TCZ therapy remission or low disease activity was achieved in 61,9% patients. Comparable results in were documented on SDAI (33%), CDAI (31%) and RAPID-3 (33,3%) scales. By week 24 of therapy maximum percentage of remissions was registered by DAS28 (71,4%).
Conclusions Remissions rates on RAPID-3 are similar to SDAI and CDAI, and 2-fold lower than the rates by DAS28 score. The difference in remissions rates is most likely explained by subjective factor in patient's self-assessment using RAPID-3, CDAI and SDAI scales vs physician's oversized assessment of patient's health status using DAS28.
Disclosure of Interest None declared